Targeting Tumor Proteins Specific to Pancreatic Cancer Cells
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.
Testing a New Drug on Advanced Pancreatic Neuroendocrine Tumors
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).
Immunotherapy for Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs…
Testing an Experimental Combination of Drugs
A clinical trial for some cancers including pancreatic cancer tests the effectiveness of a checkpoint inhibitor and an antisense oligonucleotide inhibitor.
Trying Targeted Treatments Used for Other Cancers
Researchers are trying kinase inhibitors that are effective for breast cancer, colorectal cancer, and melanoma on pancreatic cancer.
Testing a Breast Cancer Drug for Other Advanced Solid Tumors
In a clinical trial, a new class of breast cancer drug called a kinase inhibitor is being tested to treat pancreatic cancer.
Investigating a Drug Used for Other Cancers
Researchers are adding the drug decitabine to gemcitabine, in a clinical trial for patients with advanced cancer that is not responding to treatment.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Trying a New Type of Treatment to Stop Advanced Pancreatic Cancer
Researchers test the chemotherapy combination of AM0010 and FOLFOX as a second-line therapy for people with metastatic pancreatic cancer.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.